Journal of Andrology Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McConnell, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McConnell, J. D.

Journal of Andrology, Vol 12, Issue 6 356-363, Copyright © 1991 by The American Society of Andrology

REVIEW

The pathophysiology of benign prostatic hyperplasia

J. D. McConnell
Division of Urology, University of Texas Southwestern Medical Center, Dallas.

Although benign prostatic hyperplasia (BPH) is one of the most common disease processes affecting the aging male, surprisingly little is known about its pathophysiology. Cause-and-effect relationships have not been established, despite intense research efforts in the last four or five decades aimed at elucidating the underlying etiology of prostatic growth in older men. Previously held notions that the clinical symptoms of BPH (prostatism) are due simply to a mass-related increase in urethral resistance are too simplistic. It is now clear that a significant portion of the symptoms are due to obstruction-induced detrusor dysfunction. Moreover, obstruction may induce a variety of neural alterations in the bladder and prostate that contribute to symptomatology. Undoubtedly, the constellation of cellular pathologies that give rise to the symptoms of BPH will be far more complex than we currently realize. Only by unraveling these complexities, however, will we be able successfully to design alternative strategies to treat, and possibly prevent BPH.


This article has been cited by other articles:


Home page
 NEJMHome page
J. D. McConnell, C. G. Roehrborn, O. M. Bautista, G. L. Andriole Jr., C. M. Dixon, J. W. Kusek, H. Lepor, K. T. McVary, L. M. Nyberg Jr., H. S. Clarke, et al.
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
N. Engl. J. Med., December 18, 2003; 349(25): 2387 - 2398.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Guo, S. Yu, A. T. Davis, and K. Ahmed
Nuclear Matrix Targeting of the Protein Kinase CK2 Signal as a Common Downstream Response to Androgen or Growth Factor Stimulation of Prostate Cancer Cells
Cancer Res., March 1, 1999; 59(5): 1146 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Ulrix, J. V. Swinnen, W. Heyns, and G. Verhoeven
Identification of the Phosphatidic Acid Phosphatase Type 2a Isozyme as an Androgen-regulated Gene in the Human Prostatic Adenocarcinoma Cell Line LNCaP
J. Biol. Chem., February 20, 1998; 273(8): 4660 - 4665.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by The American Society of Andrology.